Maternal use of non-TNF inhibitor biologic, tofacitinib pose minimal infectious risk to offspring

ATLANTA — The use of either non-TNF inhibitor biologics or tofacitinib for chronic inflammatory diseases during pregnancy did not significantly increase risk for serious infections among infants, according to findings presented at the 2019 ACR/ARP Annual Meeting.
“Infants could be exposed to therapeutic and potentially supratherapeutic levels of biologic and small-molecule drugs during pregnancy, leading to concerns that these agents could cause immunosuppression and, therefore, serious infection in offspring,” Evelyne Vinet, MD, PhD, associate professor of rheumatology and

Source link

Related posts

TRIM27 mediates STAT3 activation at retromer-positive structures to promote colitis and colitis-associated carcinogenesis


Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan


Table of Contents


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy